Verona Pharma plc

As of June 30, 2025, Verona Pharma plc has 687.93M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 26.02, and the price-to-book ratio stands at -11.05.

These figures are as of June 30, 2025. The EV/Sales ratio of 25.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Verona Pharma plc trades at an EV/FCF ratio of 176.93, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2025, Verona Pharma plc maintains a current ratio of 10.71, meaning it holds 10.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 87.82, indicating elevated leverage, while an interest coverage ratio of -1.42 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2025. Return on assets (ROA) is negative at -16.12, reflecting losses generated across the asset base. Inventory turnover of 2.50 indicates how many times Verona Pharma plc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2025, Verona Pharma plc posted a gross margin of 95.15, reflecting its pricing power and cost economics. The operating margin of -24.29 and net profit margin of -36.62 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Free cash flow yield is negative at -1.22: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.83, meaning Verona Pharma plc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2025, Verona Pharma plc has an Altman Z-Score of 11.48, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.